| Abbreviation or jargon used | Abbreviation expanded | Significance |
| ADME | Absorption, distribution, metabolism, elimination | Progress of a medicine in an organism |
| AMM | Marketing authorizations | |
| BPL | Good laboratory practises | All the international norms of methodology, in laboratory, clinical or manufacturing practise, |
| BPC | Good clinical practises | |
| BPF | Good manufacturing practises | |
| CdB | Croix de Berny | Aventis unit grouping a part of the clinical development |
| CPR | Romainville production centre | Production factory of Aventis at 111 rte de Noisy |
| CRVA | Vitry / Alforville research centre | |
| CRO | Contract research organisation | Unit of sub-contracting of clinical development |
| DMPK | Distribution, metabolism & pharmacokinetic | Progress of a medicine in the organism |
| EDC | Early development candidate | Product in pre-clinic survey |
| EMEA | European Medicine Agency | |
| FDA | Food & drug administration | American agency which delivers the AMMs |
| GRAMS | Aventis jargon designating the services of the regulatory bodies | |
| HERG | Human ether a gogo related gene | In vitro test permitting to foresee a deleterious effect of a molecule on the electrocardiogram (QT). |
| Hit | Chemical head of series capable of supplying some « leads » | |
| HTS | High throuput screening | High speed molecular “sifting” |
| lead | Potential EDC but improvable | |
| PR | Product realisation | Designate the services of (and bound to them) clinical studies IIb and III |
| R&D | Research and development | |
| NMR | Nuclear magnetic resonance | Methodology capable of determining the atomic composition of a molecule |
| Rmv | Romainville | |
| SNC | Central nervous system |